$12.71
9.15% today
Nasdaq, Apr 04, 09:15 pm CET
ISIN
US00773J1034
Symbol
SYRE
Sector
Industry

Aeglea BioTherapeutics Inc Stock price

$13.99
-3.95 22.02% 1M
-14.38 50.69% 6M
-9.29 39.91% YTD
-20.67 59.64% 1Y
-50.26 78.23% 3Y
-86.26 86.04% 5Y
-230.26 94.27% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-1.50 9.68%
ISIN
US00773J1034
Symbol
SYRE
Sector
Industry

Key metrics

Market capitalization $843.00m
Enterprise Value $395.73m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.33
Revenue growth (TTM) Revenue growth -100.00%
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-208.57m
Free Cash Flow (TTM) Free Cash Flow $-157.82m
Cash position $603.09m
EPS (TTM) EPS $-3.16
P/E forward negative
Short interest 24.23%
Show more

Is Aeglea BioTherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Aeglea BioTherapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Aeglea BioTherapeutics Inc forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Aeglea BioTherapeutics Inc forecast:

Buy
90%
Hold
10%

Financial data from Aeglea BioTherapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 46 46
20% 20%
-
- Research and Development Expense 163 163
82% 82%
-
-209 -209
63% 63%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -209 -209
62% 62%
-
Net Profit -151 -151
59% 59%
-

In millions USD.

Don't miss a Thing! We will send you all news about Aeglea BioTherapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aeglea BioTherapeutics Inc Stock News

Neutral
PRNewsWire
8 days ago
Preclinical data demonstrates that SPY003 is highly potent and has potential forquarterly or biannual dosing, suggesting opportunity for improved efficacy andconvenience over first-generation anti-IL-23 monoclonal antibodies  Interim pharmacokinetic and safety data from healthy volunteers for SPY003 anticipatedin the second half of 2025 Subject to interim results, Spyre expects to incorporate S...
Neutral
PRNewsWire
28 days ago
WALTHAM, Mass. , March 7, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independ...
Positive
Seeking Alpha
about one month ago
Spyre Therapeutics is emerging as a key player in inflammatory bowel disease, with a focus on pathway-specific monoclonal antibodies for superior disease control. The company has a healthy balance sheet with $603.1 million in cash, providing a four-year runway at its current burn rate. SYRE's innovative combination therapy approach targets multiple inflammatory pathways, aiming for better effic...
More Aeglea BioTherapeutics Inc News

Company Profile

Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.

Head office United States
CEO Cameron Turtle
Employees 65
Founded 2013
Website www.spyre.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today